Cowden Syndrome

This content has been reviewed and approved by

William J. Gradishar, MD FACP
Director, Breast Medical Oncology, Professor of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
 

The risk for breast cancer is increased with Cowden syndrome. This is a rare inherited disorder that is also associated with certain noncancerous features. Cowden syndrome is associated with the following characteristics:

  • Multiple hamartomatous growths (benign [noncancerous] tumors of normal tissue) of the skin and other organs, usually present in women by their late 20s
  • Macrocephaly (increased head size)
  • Increased risk of breast cancer, with an average age of onset ranging from 38 to 46 years old
  • Increased risk of thyroid cancer
  • Increased risk of endometrial cancer

Other features can include noncancerous thyroid growths, intestinal polyps, lipomas (benign fatty tumors), fibromas, uterine fibroids, and fibrocystic disease of the breast.

What causes Cowden syndrome?

Cowden syndrome is caused by mutations in a gene on chromosome 10 known as PTEN. About 80 percent of people whose symptoms meet the criteria for a diagnosis of Cowden syndrome have a PTEN mutation. People with a PTEN mutation have a 25 percent to 50 percent lifetime risk of breast cancer. They also have about a 10 percent risk of thyroid cancer and perhaps up to a 10 percent risk of uterine cancer, although this risk is still being studied.

The PTEN gene is a type of tumor suppressor gene. It usually controls cell growth and cell death. Both copies of a tumor suppressor gene must be altered (mutated) before a person will develop cancer. With Cowden syndrome, the first mutation is inherited from either the mother or the father. It is therefore present in all cells of the body. This is called a germline mutation.

Whether a person who has a germline mutation gets cancer and where the cancer develops depends on where (which cell type) the second mutation occurs. For example, if the second mutation is in the thyroid, then thyroid cancer may develop. If it is in the breast, breast cancer may develop. But other mutations are needed too to lead to cancer. Mutation of both copies of PTEN is just the first step in the process. What causes these additional mutations is unknown. Possible causes include chemical, physical, or biologic agents in the environment or chance errors that happen when cells reproduce.

Some people who have inherited one PTEN mutation never develop cancer because they never get the second mutation. This can make the cancer appear to skip generations in a family, when in reality the mutation is present. People with a mutation, regardless of whether they develop cancer, have a 50-50 chance of passing the mutation on to their children.

The PTEN gene is not located on the sex chromosomes. This means that mutations can be inherited from the mother's or the father's side of the family.


Hereditary Breast Ovarian Cancer Syndrome  
Li-Fraumeni Syndrome 
Peutz-Jeghers Syndrome 

This content was last modified on May 18, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health